fused triazoles are of interest due to their various biological
activities4 and also clinical applications5 (viz. alprazolam,
estazolam, etc.). On the other hand, the morpholine moiety is
found in a diverse range of bioactive agents including antide-
pressant, antileukemia, NK-1 receptor antagonist, fungicide, etc.6
For example, reboxetine6a is used as an antidepressant drug to
treat clinical depression, attention deficit disorder, panic disorder,
hyperactivity, etc., and fenpropimorph6d is extensively used in
agriculture as a fungicide, mainly to control fungal attacks in
cereals. Presently the world drug index contains more than 100
drugs having this structural feature in different forms including
scaffold, side-chain, fused-ring, etc. The reason behind the
extensive use of the morpholine core by pharmaceutical
industries is primarily the likely improvement in pharamaco-
kinetics effected by this structural unit. Therefore, it would be
attractive to develop a straightforward and convenient method
for the synthesis of morpholines fused with 1,2,3-triazole, which
would pave the way for the preparation of a wide variety of
different bioactive compounds. Although there are numerous
methods for the synthesis of individual 1,2,3-triazoles7 and
morpholines,8 only a few methods exist in the literature for some
specific 1,2,3-triazolo-morpholine analogs,9 adopting multistep
procedures through conventional reaction pathways. Therefore,
there remains a need for a scalable, efficient, and general method
for this important class of compounds, particularly using
transition-metal-catalyzed one-pot reactions.
Expedient and Rapid Synthesis of
1,2,3-Triazolo[5,1-c]morpholines through
Palladium-Copper Catalysis
Chinmay Chowdhury,* Sanjukta Mukherjee, Bimolendu Das,
and Basudeb Achari
Chemistry DiVision, Indian Institute of Chemical Biology
(unit of CSIR), 4, Raja S. C. Mullick Road, JadaVpur,
Kolkata 700032, India
ReceiVed February 25, 2009
A one-pot approach using palladium-copper as catalyst has
been developed for the synthesis of morpholines fused with
1,2,3-triazole. Good regioselectivity, mild reaction conditions,
high yields and short reaction time are the hallmarks of this
method.
In the course of our research activities directed toward the
synthesis of various heterocycles10 of biological interests using
Because of the abundance of medium-sized heterocyclic
scaffolds in many natural products, drugs, and preclinical leads,
synthesis of these compounds through novel methodologies that
achieve the formation of multiple bonds in one operation is one
of the major challenges in organic synthesis. Such processes
need to avoid multiple steps, protection and deprotections, drain
of resources, and long reaction times, thereby constituting
environmentally benign and atom-economic methods. To this
end, use of a catalytic amount of transition metals to trigger
the process is being recognized as a powerful means. In this
context, one particular area that has witnessed significant interest
over the past few years is azide-alkyne cycloaddition. The
importance of this reaction was enhanced significantly after the
discovery of “click-reaction”.1
(3) (a) Scheel, A. J.; Komber, H.; Voit, B. I. Macromol. Rapid Commun.
2004, 25, 1175. (b) Van Steenis, D. J. V. C.; David, O. R. P.; Van Strijdonck,
G. P. F.; Van Maarseveen, J. H.; Reek, J. N. H. Chem. Commun. 2005, 4333.
(c) Laurent, B. A.; Grayson, S. M. J. Am. Chem. Soc. 2006, 128, 4238. (d)
Angell, Y. L.; Burgess, K. Chem. Soc. ReV. 2007, 36, 1674, and references
therein.
(4) (a) Jantova, S.; Letasiova, S.; Repicky, A.; Ovadekova, R.; Lakatos, B. Cell
Biochem. Funct. 2006, 24, 519. (b) Lauria, A.; Guarcello, A.; Dattolo, G.; Almerico,
A. M. Tetrahedron Lett. 2008, 49, 1847. (c) Kelley, J. L.; Koble, C. S.; Davis,
R. G.; McLean, E. W.; Soroko, F. E.; Copper, B. R. J. Med. Chem. 1995, 38, 4131.
(d) Katritzky, A. R.; Zhang, Y.; Singh, S. K. Heterocycles 2003, 60, 1225.
(5) (a) Thomas, A. W. Bioorg. Med. Chem. Lett. 2002, 12, 1881. (b) Broggini,
G.; Molteni, G.; Terraneo, A.; Zecchi, G. Tetrahedron 1999, 55, 14803.
(6) (a) Hajos, M.; Fleishaker, J. C.; Filipiak-Reisner, J. K.; Brown, M. T.;
Wong, E. H. F. CNS Drug ReV. 2004, 10, 23. (b) Jakubowska, J.; Wasowska-
Lukawska, M.; Czyz, M. Eur. J. Pharmacol. 2008, 596, 41. (c) Hale, J. J.; Mills,
S. G.; MacCoss, M.; Shah, S. K.; Qi, H.; Mathre, D. J.; Cascieri, M. A.; Sadowski,
S.; Strader, C. D.; MacIntyre, D. E.; Metzger, J. M. J. Med. Chem. 1996, 39,
1760. (d) Dieckmann, H.; Stockmaier, M.; Kreuzig, R.; Bahadir, M. Fresenius’
J. Anal. Chem. 1993, 345, 784.
Among the approaches to C-C and/or C-N bond-forming
reactions leading to various heterocycles, 1,2,3-triazoles have
received special interest because of their potent use ranging from
medicinal chemistry2 to material science.3 More importantly,
(7) (a) Gil, M. V.; Arevalo, M. J.; Lopez, O. Synthesis 2007, 1589. (b)
Chuprakov, S.; Chernyak, N.; Dudnik, A. S.; Gevorgyan, V. Org. Lett. 2007, 9,
2333. (c) Krivopalov, V. P.; Shkurko, O. P. Russ. Chem. ReV. 2005, 74, 339.
(d) Godovikova, T. I.; Ignateva, E. L.; Khmelnitskii, L. I. Chem. Heterocycl.
Compd. 1989, 25, 113.
(8) (a) See review article: Wijtmans, R.; Vink, M. K. S.; Schoemaker, H. E.;
Delft, F. L. V.; Blaauw, R. H.; Rutjes, F. P. J. T. Synthesis 2004, 641. (b)
Albanese, D.; Salsa, M.; Landini, D.; Lupi, V.; Penso, M. Eur. J. Org. Chem.
2007, 2107. (c) Henegar, K. E. J. Org. Chem. 2008, 73, 3662.
(9) Pericas and co-workers synthesized 1,2,3-triazolo-morpholines through
conventional thermal cycloaddition approach. For details, see:(a) Oliva, A. I.;
Christmann, U.; Font, D.; Cuevas, F.; Ballester, P.; Buschmann, H.; Torrens,
A.; Yenes, S.; Pericas, M. A. Org. Lett. 2008, 10, 1617. (b) Medaer, B. P.; Van
Aken, K. J.; Hoornaert, G. J. Tetrahedron 1996, 52, 8813.
(10) (a) Chowdhury, C.; Mondal, S. B.; Achari, B. Tetrahedron Lett. 2005,
46, 8531. (b) Achari, B.; Mondal, S. B.; Dutta, P. K.; Chowdhury, C. Synlett
2004, 2449. (c) Chowdhury, C.; Chaudhuri, G.; Guha, S.; Mukherjee, A. K.;
Kundu, N. G. J. Org. Chem. 1998, 63, 1863. (d) Chowdhury, C.; Kundu, N. G.
Chem. Commun. 1996, 1067.
(1) (a) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew.
Chem., Int. Ed. 2002, 41, 2596. (b) Tornoe, C. W.; Christensen, C.; Meldal, M. J.
Org. Chem. 2002, 67, 3057. (c) Chan, T. R.; Hilgraf, R.; Sharpless, K. B.; Fokin,
V. V. Org. Lett. 2004, 6, 2853. (d) Feldman, A. K.; Colasson, B.; Fokin, V. V.
Org. Lett. 2004, 6, 3897. (e) Zhang, L.; Chen, X.; Xue, P.; Sun, H. H. Y.; Williams,
I. D.; Sharpless, K. B.; Fokin, V. V.; Jia, G. J. Am. Chem. Soc. 2005, 127, 15998.
(f) Kalisiak, J.; Sharpless, K. B.; Fokin, V. V. Org. Lett. 2008, 10, 3171.
(2) For a recent review see: (a) Tron, G. C.; Pirali, T.; Billington, R. A.;
Canonico, P. L.; Sorba, G.; Genazzani, A. A. Med. Res. ReV. 2008, 28, 278. (b)
Lee, T.; Cho, M.; Ko, S.-Y.; Youn, H.-J.; Back, D. J.; Cho, W.-J.; Kang, C.-Y.;
Kim, S. J. Med. Chem. 2007, 50, 585. (c) Li, W.; Xia, Y.; Fan, Z.; Qu, F.; Wu,
Q.; Peng, L. Tetrahedron Lett. 2008, 49, 2804. (d) Pfaller, M. A.; Messer, S.;
Jones, R. N. Antimicrob. Agents Chemother. 1997, 41, 233.
3612 J. Org. Chem. 2009, 74, 3612–3615
10.1021/jo900428j CCC: $40.75 2009 American Chemical Society
Published on Web 04/03/2009